Pharmacovigilance Market Analysis, Size, Share & Growth Forecast 2026–2034

AI NLP Extraction of Adverse Events From Clinical Notes, Social Media, and Literature Enabling Comprehensive Signal Surveillance Across Multiple Sources That Manual Case Processing Cannot Monitor at Large Drug Portfolio Volume Is Transforming Pharmacovigilance Operational Efficiency.Oracle Safety, Veeva Vault Safety, and specialist vendors including Cognizant and Saama Technologies have deployed natural language processing to automate case narrative coding and medical concept extraction from adverse event reports, reducing the per-case processing time from 2-3 hours to under 30 minutes while improving consistency over manual coding. The FDA's Sentinel System applying distributed data analysis across 53 million electronic health records enables near-real-time safety signal detection from administrative claims and EMR data that supplements traditional spontaneous reporting through FAERS. Regeneron's voluntary safety signal monitoring initiative sharing anonymised genomic and phenotypic data from patients experiencing serious adverse events with FDA's Platform Technology demonstrates the industry's move toward proactive collaborative pharmacovigilance that exceeds regulatory minimum requirements.

EHR Population-Scale Adverse Event Detection Through FDA Sentinel System and EU DARWIN EU Distributed Networks Providing the Denominator Data That Spontaneous Reporting Lacks Is Enabling the Disproportionality Analysis That Identifies Real-World Safety Signals at Scale.Aetiologics's electronic health record mining platform and IQVIA's LifeLink health plan database enable cohort studies in 10-plus million patients that identify rare adverse events with 50-100 times the statistical power of Phase 3 clinical trial populations, providing the causal signal that spontaneous reports suggest but cannot confirm without the exposed versus unexposed comparison that real-world databases provide. EMA's EU PAS Register and FDA's Sentinel Surveillance System mandate that pharmaceutical companies design post-authorisation safety studies using established electronic health record databases rather than the costly primary data collection that traditional Phase 4 safety studies required. The convergence of regulatory real-world evidence requirements with the commercial pharmacovigilance market has driven consolidation where IQVIA, Evidera, and ICON's real-world evidence divisions provide integrated safety signal analysis from spontaneous reports plus real-world database validation.

REMS and DHPC Risk Minimisation Programme Implementation for Serious Identified Risks Ensuring Prescriber and Patient Understanding of Monitoring Requirements Is the Regulatory Obligation That Translates the Safety Signal Into the Managed Risk That Market Access Requires.FDA's Pediatric Safety Reporting Plan requirement for new drug approvals mandates specific paediatric adverse event coding and reporting that had previously been incompletely captured within adult-centric FAERS spontaneous reporting where paediatric patients represent under 5% of total reports. EMA's Paediatric Regulation requiring companies to submit paediatric investigation plans for any drug likely to be used in children has generated over 800 completed paediatric studies since 2007 and substantially expanded pharmacovigilance evidence in the under-18 population that had historically lacked the real-world safety data accumulated from decades of adult use. The challenge of small paediatric patient numbers that limit statistical power for rare adverse event signal detection is being addressed through European Paediatric Safety Task Force proposals for shared access to paediatric adverse event databases across national regulators that aggregate sufficient numbers for meaningful pharmacoepidemiological analysis.

For related market intelligence, see the Cro Market.